TRAIL was initially considered an attractive anticancer agent because of its ability to selectively induce cancer cell-specific apoptosis in multiple cell lines; however, clinical trials with TRAIL or anti-TRAIL receptor antibodies yielded disappointing results [3,4,5,6,7]. This evidence concerns the gene TNFSF10 and cancer.